- Home
- NLSP vs VINC Comparison
NLSP vs VINC Comparison
Compare NLSP & VINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- VINC
- Stock Information
- Founded
- NLSP 2015
- VINC 2019
- Country
- NLSP Switzerland
- VINC United States
- Employees
- NLSP N/A
- VINC N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- VINC Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- VINC Health Care
- Exchange
- NLSP Nasdaq
- VINC Nasdaq
- Market Cap
- NLSP 6.2M
- VINC 6.2M
- IPO Year
- NLSP 2021
- VINC N/A
- Fundamental
- Price
- NLSP $1.81
- VINC $0.12
- Analyst Decision
- NLSP
- VINC Buy
- Analyst Count
- NLSP 0
- VINC 2
- Target Price
- NLSP N/A
- VINC $2.00
- AVG Volume (30 Days)
- NLSP 2.2M
- VINC 21.7M
- Earning Date
- NLSP 10-18-2024
- VINC 11-12-2024
- Dividend Yield
- NLSP N/A
- VINC N/A
- EPS Growth
- NLSP N/A
- VINC N/A
- EPS
- NLSP N/A
- VINC N/A
- Revenue
- NLSP N/A
- VINC N/A
- Revenue This Year
- NLSP N/A
- VINC N/A
- Revenue Next Year
- NLSP N/A
- VINC N/A
- P/E Ratio
- NLSP N/A
- VINC N/A
- Revenue Growth
- NLSP N/A
- VINC N/A
- 52 Week Low
- NLSP $1.73
- VINC $0.10
- 52 Week High
- NLSP $20.80
- VINC $9.37
- Technical
- Relative Strength Index (RSI)
- NLSP 40.38
- VINC 31.85
- Support Level
- NLSP $1.87
- VINC $0.10
- Resistance Level
- NLSP $2.08
- VINC $0.16
- Average True Range (ATR)
- NLSP 0.20
- VINC 0.02
- MACD
- NLSP 0.01
- VINC -0.01
- Stochastic Oscillator
- NLSP 2.33
- VINC 9.54
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.